- Conditions
- Atopic Dermatitis
- Interventions
- Rocatinlimab vial injection, Rocatinlimab prefilled syringe
- Drug · Combination Product
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 711
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atopic Dermatitis
- Interventions
- LY3375880, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Fountain Valley, California • Los Angeles, California • Northridge, California + 11 more
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
- Interventions
- Specimen sample
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Atopic Dermatitis
- Interventions
- Pimecrolimus
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Atopic Dermatitis
- Interventions
- Sponsor Test Products
- Other
- Lead sponsor
- Burt's Bees Inc.
- Industry
- Eligibility
- 6 Months to 7 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Richardson, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- KHK4083, Placebo
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Huntington Beach, California • Irvine, California • Los Angeles, California + 10 more
- Conditions
- Mild Atopic Asthma
- Interventions
- BITS7201A, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Atopic Dermatitis
- Interventions
- KLH carrier-protein
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- ENV-294, Placebo
- Drug
- Lead sponsor
- Enveda Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 13
- States / cities
- Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more
- Conditions
- Atopic Dermatitis
- Interventions
- IDP-124 Lotion, IDP-124 Vehicle Lotion
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 328 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Fremont, California
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- SkinTracker Mobile App
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 11 participants
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Atopy, Atopic Dermatitis Eczema, Wheezing, Food Allergy in Infants
- Interventions
- Not listed
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 0 Days to 7 Days
- Enrollment
- 221 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Asthma
- Interventions
- Rhinovirus
- Biological
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Eczema, Atopic Dermatitis
- Interventions
- Amlitelimab, Placebo
- Drug
- Lead sponsor
- Kymab Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Fremont, California • Sacramento, California • Boca Raton, Florida + 16 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Not listed
- Lead sponsor
- Rady Children's Hospital, San Diego
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 3
- States / cities
- San Diego, California • San Francisco, California • Chicago, Illinois
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 48
- States / cities
- Anniston, Alabama • North Little Rock, Arkansas • Canoga Park, California + 38 more
- Conditions
- Allergic Rhinitis
- Interventions
- Placebo, VAK694, Fluticasone
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Duncansville, Pennsylvania
- Conditions
- Atopic Dermatitis
- Interventions
- DSXS topical
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Hawthorne, New York
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 160
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more
- Conditions
- Atopic Asthma
- Interventions
- CURCUMIN, no intervention other than stopping study
- Dietary Supplement · Other
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Atopic Dermatitis
- Interventions
- RVT-501 0.5% topical ointment
- Drug
- Lead sponsor
- Dermavant Sciences GmbH
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 12
- States / cities
- Anniston, Alabama • Irvine, California • Jacksonville, Florida + 7 more
- Conditions
- Atopic Dermatitis
- Interventions
- PF-04965842 200 mg, PF-04965842 100 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Encinitas, California • Los Angeles, California • Largo, Florida + 5 more
- Conditions
- Psoriasis, Atopic Dermatitis
- Interventions
- In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
- Device · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California